Anti-FA10/ F10/ FX monoclonal antibody
Anti-FA10/ F10/ FX antibody for FACS & in-vivo assay
Go to F10/F10 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T84631-Ab-1/ GM-Tg-hg-T84631-Ab-2 | Anti-Human F10 monoclonal antibody | Human |
GM-Tg-rg-T84631-Ab-1/ GM-Tg-rg-T84631-Ab-2 | Anti-Rat F10 monoclonal antibody | Rat |
GM-Tg-mg-T84631-Ab-1/ GM-Tg-mg-T84631-Ab-2 | Anti-Mouse F10 monoclonal antibody | Mouse |
GM-Tg-cynog-T84631-Ab-1/ GM-Tg-cynog-T84631-Ab-2 | Anti-Cynomolgus/ Rhesus macaque F10 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T84631-Ab-1/ GM-Tg-felg-T84631-Ab-2 | Anti-Feline F10 monoclonal antibody | Feline |
GM-Tg-cang-T84631-Ab-1/ GM-Tg-cang-T84631-Ab-2 | Anti-Canine F10 monoclonal antibody | Canine |
GM-Tg-bovg-T84631-Ab-1/ GM-Tg-bovg-T84631-Ab-2 | Anti-Bovine F10 monoclonal antibody | Bovine |
GM-Tg-equg-T84631-Ab-1/ GM-Tg-equg-T84631-Ab-2 | Anti-Equine F10 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T84631-Ab-1/ GM-Tg-hg-T84631-Ab-2; GM-Tg-rg-T84631-Ab-1/ GM-Tg-rg-T84631-Ab-2; GM-Tg-mg-T84631-Ab-1/ GM-Tg-mg-T84631-Ab-2; GM-Tg-cynog-T84631-Ab-1/ GM-Tg-cynog-T84631-Ab-2; GM-Tg-felg-T84631-Ab-1/ GM-Tg-felg-T84631-Ab-2; GM-Tg-cang-T84631-Ab-1/ GM-Tg-cang-T84631-Ab-2; GM-Tg-bovg-T84631-Ab-1/ GM-Tg-bovg-T84631-Ab-2; GM-Tg-equg-T84631-Ab-1/ GM-Tg-equg-T84631-Ab-2 |
Products Name | Anti-F10 monoclonal antibody |
Format | mab |
Target Name | F10 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-F10 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-ab-177 | Pre-Made Emicizumab biosimilar, Bispecific mAb, Anti-F9;F10 Antibody: Anti-FIX/HEMB/P19/PTC/THPH8;FX/FXA therapeutic antibody |
Target Antigen | Products Developing | Multi-species FA10/ F10/ FX VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMAP000423 | Human F10 Adenovirus plasmid |
ORF Viral Vector | vGMAP000423 | Human F10 Adenovirus particle |
ORF Viral Vector | pGMLPm002072 | mouse F10 Lentivirus plasmid |
ORF Viral Vector | vGMLPm002072 | mouse F10 Lentivirus particle |
Target information
Target ID | GM-T84631 |
Target Name | F10 |
Gene ID | 2159,14058,29243,714132,280787,100067094 |
Gene Symbol and Synonyms | Cf10,F10,FX,FXA |
Uniprot Accession | P00742,Q63207,P00743 |
Uniprot Entry Name | FA10_HUMAN,FA10_RAT,FA10_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index |
Disease | N/A |
Gene Ensembl | ENSG00000126218 |
Target Classification | N/A |
The target: F10, gene name: F10, also named as FX, FXA. This gene encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. This factor undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides. [provided by RefSeq, Aug 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.